Barely Significant
← all excerpts

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.

Vasc Health Risk Manag · 2013 · PMC3673969 · PMID 23761972

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

highly significantP < 0.0001actually significant
71 Analysis of the HPS also assessed simvastatin efficacy in subjects with and without diabetes and showed an effect consistent with the full cohort; 72 that is, simvastatin produced highly significant reductions (22%; P < 0.0001) in the first event rate for major coronary events, strokes, and revascularizations in subjects with type 2 diabetes.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.